Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 9;74(7):1303-1312.
doi: 10.1093/cid/ciab757.

Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria

Sharon Ong'uti  1 , Mary Czech  1 , Elizabeth Robilotti  2 , Marisa Holubar  1
Affiliations
Review

Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria

Sharon Ong'uti et al. Clin Infect Dis. .

Abstract

Cefiderocol is a novel injectable siderophore cephalosporin that hijacks the bacterial iron transport machinery to facilitate cell entry and achieve high periplasmic concentrations. It has broad in vitro activity against gram-negative bacteria, including multidrug-resistant (MDR) organisms such as carbapenem-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii. It was approved by the US Food and Drug Administration for the treatment of complicated urinary tract infections and nosocomial pneumonia based on clinical trials that demonstrated noninferiority to comparators. In this review, we summarize the available in vitro and clinical data, including recent evidence from 2 phase 3 clinical trials (APEKS-NP and CREDIBLE-CR), and discuss the place of cefiderocol in the clinician's armamentarium against MDR gram-negative infections.

Keywords: carbapenem resistant Enterobacterales; cefiderocol; extended spectrum beta; gram; lactamase producing (ESBL); multidrug resistant; negative bacteria.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cefiderocol’s structural components responsible for antibacterial activity. *Image source: https://en.wikipedia.org/wiki/Cefiderocol#/media/File:Cefiderocol.svg. I, the copyright holder of this work, release this work into the public domain. This applies worldwide. In some countries this may not be legally possible; if so: I grant anyone the right to use this work for any purpose, without any conditions, unless such conditions are required by law.
See this image and copyright information in PMC

References

    1. World Health Organization. Ten threats to global health in 2019. 2019. Available at: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-.... Accessed 22 September 2021.
    1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2019. 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re.... Accessed 22 September 2021.
    1. Echols R, Ariyasu M, Nagata TD. Pathogen-focused clinical development to address unmet medical need: cefiderocol targeting carbapenem resistance. Clin Infect Dis 2019; 69:559–64. - PMC - PubMed
    1. Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis 2019; 69:538–43. - PMC - PubMed
    1. Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs 2019; 79:271–89. - PubMed

MeSH terms